Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.15
IRWD's Cash to Debt is ranked lower than
62% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. IRWD: 1.15 )
Ranked among companies with meaningful Cash to Debt only.
IRWD' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 60.61 Max: N/A
Current: 1.15
Equity to Asset 0.15
IRWD's Equity to Asset is ranked lower than
95% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IRWD: 0.15 )
Ranked among companies with meaningful Equity to Asset only.
IRWD' s Equity to Asset Range Over the Past 10 Years
Min: -1.86  Med: 0.37 Max: 0.74
Current: 0.15
-1.86
0.74
F-Score: 5
Z-Score: 0.15
M-Score: -1.50
WACC vs ROIC
8.80%
-251.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -40.71
IRWD's Operating margin (%) is ranked lower than
85% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.49 vs. IRWD: -40.71 )
Ranked among companies with meaningful Operating margin (%) only.
IRWD' s Operating margin (%) Range Over the Past 10 Years
Min: -1101.36  Med: -204.91 Max: -48.43
Current: -40.71
-1101.36
-48.43
Net-margin (%) -65.76
IRWD's Net-margin (%) is ranked lower than
87% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. IRWD: -65.76 )
Ranked among companies with meaningful Net-margin (%) only.
IRWD' s Net-margin (%) Range Over the Past 10 Years
Min: -1192.31  Med: -197.18 Max: -48.34
Current: -65.76
-1192.31
-48.34
ROE (%) -123.99
IRWD's ROE (%) is ranked lower than
96% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. IRWD: -123.99 )
Ranked among companies with meaningful ROE (%) only.
IRWD' s ROE (%) Range Over the Past 10 Years
Min: -299.34  Med: -155.35 Max: -48.14
Current: -123.99
-299.34
-48.14
ROA (%) -21.96
IRWD's ROA (%) is ranked lower than
83% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. IRWD: -21.96 )
Ranked among companies with meaningful ROA (%) only.
IRWD' s ROA (%) Range Over the Past 10 Years
Min: -107.22  Med: -38.81 Max: -22.85
Current: -21.96
-107.22
-22.85
ROC (Joel Greenblatt) (%) -300.81
IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.14 vs. IRWD: -300.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IRWD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1275.86  Med: -355.09 Max: -190.56
Current: -300.81
-1275.86
-190.56
Revenue Growth (3Y)(%) -9.30
IRWD's Revenue Growth (3Y)(%) is ranked lower than
82% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IRWD: -9.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IRWD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.65 Max: 30.3
Current: -9.3
0
30.3
EBITDA Growth (3Y)(%) 6.90
IRWD's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. IRWD: 6.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IRWD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -0.35 Max: 51.9
Current: 6.9
0
51.9
EPS Growth (3Y)(%) 13.70
IRWD's EPS Growth (3Y)(%) is ranked higher than
62% of the 498 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. IRWD: 13.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IRWD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.10 Max: 54.2
Current: 13.7
0
54.2
» IRWD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

IRWD Guru Trades in Q2 2015

Jim Simons 69,303 sh (New)
Steven Cohen 1,378,600 sh (+83.81%)
Vanguard Health Care Fund 4,367,387 sh (+3.21%)
» More
Q3 2015

IRWD Guru Trades in Q3 2015

Paul Tudor Jones 12,514 sh (New)
Steven Cohen 1,612,400 sh (+16.96%)
Vanguard Health Care Fund 4,367,387 sh (unchged)
Jim Simons 31,253 sh (-54.90%)
» More
Q4 2015

IRWD Guru Trades in Q4 2015

Jim Simons 242,553 sh (+676.10%)
Paul Tudor Jones 26,514 sh (+111.87%)
Vanguard Health Care Fund 4,367,387 sh (unchged)
Samuel Isaly 1,237,800 sh (unchged)
Steven Cohen 1,537,900 sh (-4.62%)
» More
Q1 2016

IRWD Guru Trades in Q1 2016

Ken Fisher 235,675 sh (New)
Vanguard Health Care Fund 4,522,387 sh (+3.55%)
Samuel Isaly 1,237,800 sh (unchged)
Jim Simons Sold Out
Steven Cohen 1,180,500 sh (-23.24%)
Paul Tudor Jones 14,044 sh (-47.03%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XTER:SAZ, NAS:ENDP, TSE:4516, SZSE:000028, SZSE:000999, SZSE:000623 » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc is an entrepreneurial pharmaceutical company. It discovers, develops and commercializes differentiated medicines that improve patient's lives.

Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.

Ratios

vs
industry
vs
history
P/B 19.68
IRWD's P/B is ranked lower than
97% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. IRWD: 19.68 )
Ranked among companies with meaningful P/B only.
IRWD' s P/B Range Over the Past 10 Years
Min: 5.45  Med: 11.22 Max: 47.65
Current: 19.68
5.45
47.65
P/S 9.46
IRWD's P/S is ranked lower than
82% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. IRWD: 9.46 )
Ranked among companies with meaningful P/S only.
IRWD' s P/S Range Over the Past 10 Years
Min: 2.63  Med: 18.96 Max: 75.43
Current: 9.46
2.63
75.43
Current Ratio 6.35
IRWD's Current Ratio is ranked higher than
83% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. IRWD: 6.35 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s Current Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.74 Max: 9.64
Current: 6.35
2.33
9.64
Quick Ratio 6.35
IRWD's Quick Ratio is ranked higher than
85% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. IRWD: 6.35 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.70 Max: 9.04
Current: 6.35
2.33
9.04
Days Inventory 28.02
IRWD's Days Inventory is ranked higher than
91% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. IRWD: 28.02 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s Days Inventory Range Over the Past 10 Years
Min: 51.22  Med: 462.06 Max: 1266.91
Current: 28.02
51.22
1266.91
Days Sales Outstanding 1.78
IRWD's Days Sales Outstanding is ranked higher than
99% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. IRWD: 1.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 8.18 Max: 889.76
Current: 1.78
0.05
889.76
Days Payable 67.07
IRWD's Days Payable is ranked lower than
54% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.00 vs. IRWD: 67.07 )
Ranked among companies with meaningful Days Payable only.
IRWD' s Days Payable Range Over the Past 10 Years
Min: 139.16  Med: 345.67 Max: 8217.61
Current: 67.07
139.16
8217.61

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.68
IRWD's Price/Tangible Book is ranked lower than
95% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. IRWD: 19.68 )
Ranked among companies with meaningful Price/Tangible Book only.
IRWD' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.98  Med: 11.48 Max: 36.86
Current: 19.68
5.98
36.86
Price/Median PS Value 0.50
IRWD's Price/Median PS Value is ranked higher than
92% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. IRWD: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
IRWD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 1.03 Max: 3.27
Current: 0.5
0.16
3.27
Earnings Yield (Greenblatt) (%) -5.00
IRWD's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. IRWD: -5.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRWD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.59  Med: 0.00 Max: 0
Current: -5
-13.59
0

More Statistics

Revenue (TTM) (Mil) $186.7
EPS (TTM) $ -0.86
Beta0.88
Short Percentage of Float23.19%
52-Week Range $7.35 - 14.28
Shares Outstanding (Mil)144.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 248 353 517
EPS ($) -0.83 -0.43 0.59
EPS without NRI ($) -0.83 -0.43 0.59
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals Aug 25 2015 
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
IRONWOOD PHARMACEUTICALS INC Financials May 19 2016
Investor turning cautious on Ironwood May 19 2016
Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference May 18 2016
Ironwood Pharmaceuticals to Present at 2016 UBS Global Healthcare Conference May 18 2016
Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week® 2016 May 17 2016
ETF’s with exposure to Ironwood Pharmaceuticals, Inc. : May 12, 2016 May 12 2016
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US :... May 11 2016
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 10 2016
Edited Transcript of IRWD earnings conference call or presentation 9-May-16 8:30pm GMT May 10 2016
Ironwood reports 1Q loss May 09 2016
Ironwood reports 1Q loss May 09 2016
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 09 2016
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update May 09 2016
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update May 09 2016
Q1 2016 Ironwood Pharmaceuticals Inc Earnings Release - After Market Close May 09 2016
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML May 06 2016
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference May 03 2016
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)